Patent License Agreement

A Patent License Agreement in the United States records the obligations the parties accept and the terms governing their arrangement.

Patent licenses in the US are governed by federal patent law — primarily Title 35 USC and the regulations of the USPTO at 37 C.F.R. Part 1 — and by general contract law principles applied at the state level. The US Court of Appeals for the Federal Circuit has exclusive appellate jurisdiction over patent matters and has developed a substantial body of patent licensing case law that practitioners across the country must follow. Key Federal Circuit precedents governing patent licenses include Lucent Technologies, Inc. v. Gateway, Inc., 580 F.3d 1301 (Fed. Cir. 2009) (royalty base and rate calculations), and Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008) (patent exhaustion doctrine).

A patent license may be exclusive or non-exclusive. An exclusive license grants the licensee the sole right to practice the patent within the licensed scope, excluding all others including the patent owner, during the license term. An exclusive licensee with 'all substantial rights' in a patent may have standing to sue infringers in its own name under the Federal Circuit's ruling in WiAV Solutions LLC v. Motorola, Inc., 631 F.3d 1257 (Fed. Cir. 2010). A non-exclusive license grants the licensee rights while preserving the licensor's ability to grant identical rights to others — as is common in standards-essential patents licensed under FRAND (fair, reasonable, and non-discriminatory) terms administered by standards bodies such as the IEEE, 3GPP, and ETSI.

Patent exhaustion — the doctrine that the first authorized sale of a patented article exhausts the patent holder's rights to control subsequent use and resale of that specific article — is a critical limitation on patent license scope. The Supreme Court's decision in Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017), clarified that domestic sales exhaust patent rights even when the patent holder imposes downstream use restrictions, but that foreign sales exhaust US patent rights only if the patent holder authorized the foreign sale with knowledge that US patent rights would be exhausted.

For pharmaceutical patents licensed to generic drug manufacturers, the patent license must address the Hatch-Waxman Act framework, 21 U.S.C. § 355, under which the patent holder's rights to seek an injunction against generic entry are defined by the drug's listing in the FDA's Orange Book. License-related antitrust issues under the Sherman Antitrust Act, 15 U.S.C. § 1, and the FTC Act, 15 U.S.C. § 45, are relevant when patent licenses are used to coordinate competitor behavior — the DOJ and FTC have issued Antitrust Guidelines for the Licensing of Intellectual Property that apply to patent license structures.

The Defend Trade Secrets Act (DTSA), 18 U.S.C. § 1836, operates alongside patent law to protect unpatented technical information disclosed during licensing negotiations. Patent license agreements frequently include NDA provisions and trade secret protections covering technical know-how that the licensor discloses to enable the licensee to implement the patented technology.

A Patent License Agreement in the United States is needed whenever a patent holder wants to authorize another party to use, manufacture, sell, or import a patented invention while retaining ownership of the patent and the right to enforce it against unauthorized users.

A Patent License Agreement is needed when a startup company or individual inventor wants to commercialize a patented technology by partnering with an established manufacturer who has the production capacity and distribution networks that the patent holder lacks. Technology licensing is a primary commercialization strategy for universities, research institutions, and independent inventors who hold patents but do not manufacture products — in 2022, US university technology licensing generated over $3 billion in licensing revenue according to the Association of University Technology Managers (AUTM).

The agreement is needed when a technology company licenses its patent portfolio to a competitor or complementary business to generate recurring royalty revenue. Major US technology companies including Qualcomm (San Diego, California), IBM (Armonk, New York), and Dolby Laboratories (San Francisco, California) derive significant revenue from patent licensing operations that require carefully drafted license agreements.

A Patent License Agreement is needed in the pharmaceutical industry when a branded drug manufacturer licenses its patents to a generic drug company as part of a settlement of patent litigation under the Hatch-Waxman Act. These 'authorized generic' license agreements must be structured to avoid FTC scrutiny as potentially anticompetitive reverse payment settlements under FTC v. Actavis, Inc., 570 U.S. 136 (2013).

The agreement is needed when a company acquires another business and needs to back-license certain patents to the selling company as part of the acquisition transaction, allowing the seller to continue using technology it developed but transferred to the buyer.

A Patent License Agreement is needed in standards-essential patent (SEP) contexts where a patent holder has committed to license its patents on FRAND terms to any implementer of a technical standard. FRAND license agreements are the subject of significant litigation in the US District Courts for the Northern District of California, Delaware, and other major patent jurisdictions.

A Patent License Agreement under US law must address every material aspect of the licensed patent rights to be enforceable and to provide both parties with the certainty they need. Ambiguous or incomplete patent licenses generate expensive litigation over the scope of the grant.

The patent identification clause must precisely identify the licensed patents: US patent numbers, publication numbers for any pending applications that are included, and whether the license covers continuations, continuations-in-part, divisionals, reissues, and foreign counterparts. An overly narrow patent identification clause can leave the licensee exposed to infringement claims on related patents; an overly broad clause may give away rights the licensor did not intend to grant.

The grant of rights clause is the operative provision defining exactly what rights are granted: the right to make, use, sell, offer for sale, and/or import the patented invention. The grant must state whether it is exclusive or non-exclusive; the geographic scope (United States only, worldwide, or specified countries); the field of use (if restricted to a specific application or market); and any sublicensing rights (express authorization is required for a licensee to sublicense under US patent law, as held in Speedplay, Inc. v. Bebop, Inc., 211 F.3d 1245 (Fed. Cir. 2000)).

The royalty structure clause specifies the financial terms: running royalties as a percentage of net sales (with a precise definition of 'net sales' that specifies deductible items such as returns, discounts, and taxes); per-unit fees; upfront license fees; milestone payments tied to regulatory approvals, product launches, or cumulative sales thresholds; and minimum annual royalties that provide the licensor with a guaranteed baseline payment. The royalty base must be carefully defined — the Federal Circuit has scrutinized royalty base calculations in cases including Lucent Technologies, 580 F.3d 1301, and requires that royalties be apportioned to the patented contribution.

The royalty reporting and audit rights clause requires the licensee to provide periodic royalty reports (typically quarterly) and grants the licensor the right to audit the licensee's books and records to verify royalty calculations. Audit rights should specify: frequency (no more than once per year in most agreements); notice period; who bears the cost of the audit (typically the licensor unless the audit reveals an underpayment exceeding a specified threshold, such as 5%); and the time period covered.

The patent prosecution and maintenance clause allocates responsibility for paying USPTO maintenance fees (due at 3.5, 7.5, and 11.5 years under 35 U.S.C. § 41) and for prosecuting continuations, continuations-in-part, and divisionals. If the licensor fails to pay maintenance fees, the patent may go abandoned — the agreement should give the licensee the right to pay maintenance fees and offset the cost against future royalties.

The infringement by third parties clause addresses who has the right and obligation to enforce the licensed patent against unauthorized users. In an exclusive license, the licensee typically has the right (and often the obligation) to sue infringers. In a non-exclusive license, the licensor retains enforcement rights. The agreement should specify cost-sharing, damage-sharing, and the consequences if one party declines to enforce.

The patent validity and indemnification clause addresses the allocation of risk if the licensed patent is later found invalid, unenforceable, or if the licensee is sued for infringement by a third party alleging that the licensed product infringes a third-party patent. Licensor warranties of patent validity are disfavored under Lear, Inc. v. Adkins, 395 U.S. 653 (1969), which held that licensees have standing to challenge the validity of licensed patents. The agreement should address licensor indemnification obligations for third-party infringement claims.

The term and termination clause specifies the duration of the license (which may not exceed the patent term — 20 years from the earliest effective filing date under 35 U.S.C. § 154), grounds for termination (material breach, bankruptcy of either party, patent invalidity), cure periods, and the post-termination obligations of both parties (return of licensed technology, cessation of sales, disposal of inventory). The forms-legal.com Patent License Agreement template addresses all critical patent licensing provisions including grant of rights, exclusivity, field of use, royalty structure, reporting obligations, audit rights, infringement enforcement, and termination procedures.